VOLITIONRX LTD

Analysis for Ticker: VNRX

Volitionrx Limited claims to build blood tests to find cancer and sepsis using high-tech names like Nu.Q Net and Nu.Q Vet. It looks like a scientific savior, but the current reality is a hollowed-out machine. On 28/04/2026, the company performed a desperate mathematical trick called a reverse stock split, crushing twenty shares into a single one just to keep the price looking high enough to stay on the exchange. The stock currently carries a BC label, which stands for Below Compliance, a public warning that the business is failing the basic financial health rules of the market. The math is a disaster because the company is burning through its final fumes while a debt predator is contractually guaranteed to suck out every penny of new demand. The current price of 2,64$ is a complete illusion, hiding the fact that the company is being eaten alive from the inside by its own financing agreements. The internal decay started on 17/03/2025, when the board of directors set up a 2024 Stock Incentive Plan to give themselves stock for free. Two months later, on 15/05/2025, they invited the first parasite into the host organism. They signed a 7,5$ million debt note with Lind Global Asset Management Xii Llc, managed by Jeff Easton and Elli Lerner. The company only received 6,25$ million in cash but instantly owed 7,5$ million back. Lind also took 13 million warrants to lock in future profits. By 30/09/2025, the treasury was almost empty, holding a mere 199.407$ in cash. The business had burned 14,2$ million in just nine months while spending 7,6$ million just on office administration. To keep the lights on, they sold shares to an existing stockholder for 300.000$ at 0,62$ each and hired JonesTrading to dump up to 30$ million more in shares on regular people.